Chronic Myelogenous Leukemia: New Targeted Therapies Take Aim at Gleevec

Published by	Decision Resources, Inc.
Published	August, 2009	Product code	98893
Content info	22 Pages
Price	US $ 3450 PDF by E-mail (Global License)

Introduction
Related Reports

Chronic Myelogenous Leukemia: New Targeted Therapies Take Aim at Gleevec published by Decision Resources, Inc. in August, 2009. This report consists of 22 Pages and the price starts from US $ 3450.

Introduction

Abstract

Introduction

Chronic myelogenous leukemia (CML) is a rare blood cancer; nonetheless, CML treatments garner substantial revenues. Despite recent advances in the treatment of this disease (most notably, targeted therapeutics such as Novartis' s Gleevec/Glivec [imatinib]), significant unmet needs remain because certain segments of the CML patient population are intolerant of or become resistant to existing therapies. Emerging therapies that focus on the unmet needs of current therapeutics have a good chance of replicating Gleevec' s success.

Questions Answered in This Report

Properly diagnosing CML is an integral part of choosing a " n effective treatment. How is CML diagnosed?
What role does genetic testing play in developing and deploying drugs for CML? What are the symptoms of CML?
Treatment options for CML are more targeted today than in recent history. How was CML previously treated? Why have targeted therapies proved to be better CML treatment options?
Despite treatment advances, opportunities remain for emerging CML agents. What are these opportunities? Are the opportunities potentially lucrative enough to motivate drug developers?

Scope

Disease overview: disease causes and indicators, physical and genetic symptoms, diagnosis, classification, epidemiology, and disease progression.
Current CML therapies: chemotherapy, interferon-alpha, targeted therapies, stem cell therapy.
Emerging CML therapies: targeted therapies, therapies focused on particular disease mutations.
Market outlook: 2008 CML market sales, opportunities for current and emerging CML therapies.

Mentioned in This Report

Bristol-Myers Squibb
ChemGenex Pharmaceuticals
CytRx
Deciphera Pharmaceuticals
Exelixis
Genzyme Genetics
Innate Pharma
Janssen Pharmaceutica
Kiadis
Novartis
Piramal Life Sciences
Roche
Schering-Plough
Wyeth

Executive Summary
- Strategic Considerations
- Stakeholder Implications
Introduction
Disease Overview
- Etiology and Pathophysiology
  - BCR-ABL-Positive Patients
  - BCR-ABL-Negative Patients
- Diagnosis and Classification
- Patient Population, Symptoms, and Disease Progression
Current Therapies
- Drug Therapies
  - Novartis' s Gleevec
  - Novartis' s Tasigna
  - Bristol-Myers Squibb' s Sprycel
  - Interferon-Alpha
  - Generic Chemotherapeutic Agents
- Progenitor Stem Cell Transplantation
  - Myeloablative Regimens
  - Allogenic Progenitor Stem Cell Transplantation
  - Autologous Progenitor Stem Cell Transplantation
Emerging Therapies
- Wyeth' s Bosutinib (SKI-606)
- Novartis' s Panobinostat (LBH-589)
- ChemGenex Pharmaceuticals' Omacetaxine Mepesuccinate
2008 Statistics and Market Outlook

Tables

1. Laboratory Features Characteristic of Chronic Myelogenous Leukemia
2. Poor Prognostic Factors for Chronic-Phase Chronic Myelogenous Leukemia
3. Commonly Used Current Therapies in the Treatment of Chronic Myelogenous Leukemia
4. Emerging Therapies for Chronic Myelogenous Leukemia
5. 2008 Worldwide Chronic Myelogenous Leukemia Market